CBD vs. THC: Key Clinical Differences Every Patient Should Know

The Core Difference: Psychoactivity

The most important clinical distinction between CBD and THC is psychoactivity. THC (Δ9-tetrahydrocannabinol) is a partial agonist at CB1 receptors in the brain — this is what produces the "high" associated with cannabis. CBD (cannabidiol) does not directly activate CB1 receptors with meaningful affinity and does not produce psychoactive effects at therapeutic doses. This single difference has profound implications for clinical use, regulatory status, and patient acceptability.

Mechanisms of Action

THC acts primarily as a partial agonist at CB1 and CB2 receptors. Its psychoactive effects result from CB1 activation in the prefrontal cortex, hippocampus, and amygdala. Its analgesic effects involve CB1 receptors in the spinal cord and periaqueductal gray. Its antiemetic effects involve CB1 receptors in the brainstem. THC also activates TRPV1 channels and modulates dopamine release in the reward pathway.

CBD has a more complex, multi-target pharmacology. It inhibits FAAH (raising anandamide levels), acts as a negative allosteric modulator of CB1 (reducing THC's psychoactivity), activates 5-HT1A receptors (anxiolytic, antiemetic), desensitizes TRPV1 channels (analgesic, anti-inflammatory), antagonizes GPR55 (anticonvulsant), and inhibits adenosine reuptake (anti-inflammatory). This multi-target profile explains CBD's broad therapeutic potential and also makes it harder to study — it is difficult to attribute effects to a single mechanism.

Evidence Base: Where Each Excels

THC has the strongest evidence for: chemotherapy-induced nausea and vomiting (FDA-approved as dronabinol and nabilone), neuropathic pain (multiple RCTs), MS spasticity (as nabiximols), and appetite stimulation in AIDS/cancer cachexia. THC also has evidence for PTSD nightmares (nabilone) and sleep onset.

CBD has the strongest evidence for: treatment-resistant epilepsy (FDA-approved as Epidiolex for Dravet syndrome and LGS), social anxiety disorder (multiple RCTs), and as an adjunct to reduce THC-induced psychoactivity. CBD has emerging evidence for PTSD, generalized anxiety, and inflammatory conditions.

Dosing: The Critical Differences

THC dosing is highly sensitive. The therapeutic window is narrow, and the dose-response relationship is often biphasic — low doses may be beneficial while high doses cause adverse effects. Clinical guidelines recommend starting at 2.5mg THC and titrating slowly. Most therapeutic effects occur at 5–15mg; recreational doses are often 10–30mg or higher.

CBD dosing is less sensitive and does not have the same narrow therapeutic window. However, effective doses in clinical trials are often much higher than those in commercial products: 150–600mg for anxiety (acute), 20mg/kg/day for epilepsy (Epidiolex). Most commercial CBD products contain 10–50mg per dose — potentially insufficient for therapeutic effects beyond mild anxiety relief. Bioavailability varies significantly by formulation.

Safety Profiles

THC's main adverse effects include psychoactive effects (euphoria, anxiety, paranoia), cognitive impairment (particularly working memory and attention), tachycardia, dry mouth, and appetite stimulation. Chronic use risks include tolerance, dependence (cannabis use disorder in ~9% of users), and potential adverse effects on adolescent brain development. THC is contraindicated in personal or family history of psychosis.

CBD is generally well-tolerated. Main adverse effects include somnolence, diarrhea, decreased appetite, and elevated liver enzymes (particularly at high doses or with valproate). CBD has significant drug interactions via CYP2C19 and CYP3A4 inhibition — it can increase levels of many medications including antiseizure drugs, antidepressants, and blood thinners. CBD does not cause dependence or withdrawal.

The Ratio Question: Why 1:1 Products Exist

Many medical cannabis products use a THC:CBD ratio rather than either compound alone. The rationale is that CBD modulates THC's psychoactive effects — acting as a "brake" on CB1 activation — while potentially contributing independent therapeutic effects. Nabiximols (Sativex), the most studied medical cannabis product, uses a 1:1 THC:CBD ratio. The optimal ratio for different conditions is not well established and likely varies by individual and indication. Higher CBD:THC ratios (e.g., 20:1) are often used when minimizing psychoactivity is a priority.